<p>Evommune, Inc.（纽约证券交易所代码：EVMN - 获取免费报告）在周二的交易中股价下跌了 6.9%。该股票最低交易价格为 17.93 美元，最后交易价格为 18.23 美元。在午盘交易中，共成交了 43,298 股，较平均交易量 317,692 股下降了 86%。该股票此前收盘价为 19.58 美元。</p>
<h2>分析师评级变动</h2>
<ul>
<li>高风险，高回报：2026 年值得关注的 3 只医疗股</li>
</ul>
<p>EVMN 已经成为多份研究报告的主题。高盛集团在 1 月 7 日的研究报告中将 Evommune 的评级上调至 “买入”。Oppenheimer 在 1 月 22 日的研究报告中开始覆盖 Evommune，给予 “跑赢大盘” 的评级，并设定 42.00 美元的目标价。William Blair 在 12 月 1 日的研究报告中开始覆盖 Evommune，给予该股票 “跑赢大盘” 的评级。Cantor Fitzgerald 在 12 月 1 日的报告中开始覆盖 Evommune 的股票，给予该公司的 “增持” 评级。最后，Evercore ISI 在 12 月 1 日的报告中开始覆盖 Evommune 的股票，给予 “跑赢大盘” 的评级，并设定 40.00 美元的目标价。两位投资分析师对该股票给予了强烈买入评级，七位给予买入评级，一位给予持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，共识目标价为 39.17 美元。</p>
<p><strong>查看我们关于 Evommune 的最新研究报告</strong></p>
<h2>Evommune 股价下跌 2.7%</h2>
<p>该股票的市值为 6.0053 亿美元，市盈率为-2.36。该公司的 50 日移动平均线为 18.54 美元。</p>
<p>Evommune（纽约证券交易所代码：EVMN - 获取免费报告）最近在 12 月 11 日发布了其财报。该公司报告每股收益（EPS）为-8.07 美元，低于分析师的共识预期（-6.58 美元）1.49 美元。该公司在该季度的收入为 1000 万美元，而分析师的预期也是 1000 万美元。</p>
<h2>Evommune 的机构交易</h2>
<p>一家对冲基金最近在 Evommune 股票中购买了新股份。根据该公司在最近向证券交易委员会提交的 13F 文件，Capricorn Fund Managers Ltd 在第四季度购买了 Evommune, Inc.（纽约证券交易所代码：EVMN - 免费报告）的新股份。该公司购买了 60,000 股，价值约为 1,027,000 美元。Capricorn Fund Managers Ltd 在最近一个季度末持有 Evommune 约 0.19% 的股份。</p>
<h2>Evommune 公司简介</h2>
<p>（获取免费报告）</p>
<p>Evommune 是一家临床阶段的生物技术公司，开发针对慢性炎症性疾病关键驱动因素的创新疗法，初步临床开发项目集中在慢性自发性荨麻疹（“CSU”）、特应性皮炎（“AD”）和溃疡性结肠炎（“UC”）上。慢性炎症是全球一个重要的健康问题，严重影响患者的生活质量，并导致危及生命的疾病。如果不加以预防，这些疾病最终会导致致命疾病，如心血管疾病、糖尿病和癌症，这些疾病占全球每五个死亡病例中的三个，并导致美国医疗系统每年约 900 亿美元的成本。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 Evommune</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>没有人告诉你的 100 万亿 AI 故事</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Evommune 吗？</h2>
<p>在您考虑 Evommune 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Evommune 并不在名单上。</p>
<p>虽然 Evommune 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

EVMN

<p>Evommune (NYSE:EVMN) 的股价在交易中下跌了 6.9%，至 18.23 美元，成交量显著减少。分析师的评级意见不一，高盛将其评级上调至 “买入”，而奥本海默则设定了 42 美元的目标价。该公司报告每股亏损 8.07 美元，未能达到预期，营收与预期一致，为 1000 万美元。最近一家对冲基金收购了 Evommune 的股份，该公司专注于慢性炎症疾病的治疗。尽管普遍评级为 “买入”，但一些分析师建议存在更好的投资机会</p>

<p>Evommune, Inc. (NYSE:EVMN - Get Free Report) shares traded down 6.9% during trading on Tuesday . The stock traded as low as $17.93 and last traded at $18.23. 43,298 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 317,692 shares. The stock had previously closed at $19.58.</p>
<div class="lb-trans"><p>Evommune, Inc.（纽约证券交易所代码：EVMN - 获取免费报告）在周二的交易中股价下跌了 6.9%。该股票最低交易价格为 17.93 美元，最后交易价格为 18.23 美元。在午盘交易中，共成交了 43,298 股，较平均交易量 317,692 股下降了 86%。该股票此前收盘价为 19.58 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>高风险，高回报：2026 年值得关注的 3 只医疗股</li>
</ul>
</div><p>EVMN has been the subject of a number of research reports. The Goldman Sachs Group upgraded Evommune to a &#34;buy&#34; rating in a research note on Wednesday, January 7th. Oppenheimer began coverage on Evommune in a research report on Thursday, January 22nd. They set an &#34;outperform&#34; rating and a $42.00 price objective for the company. William Blair started coverage on Evommune in a research report on Monday, December 1st. They issued an &#34;outperform&#34; rating on the stock. Cantor Fitzgerald started coverage on shares of Evommune in a report on Monday, December 1st. They set an &#34;overweight&#34; rating for the company. Finally, Evercore ISI assumed coverage on shares of Evommune in a report on Monday, December 1st. They issued an &#34;outperform&#34; rating and a $40.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $39.17.</p>
<div class="lb-trans"><p>EVMN 已经成为多份研究报告的主题。高盛集团在 1 月 7 日的研究报告中将 Evommune 的评级上调至 “买入”。Oppenheimer 在 1 月 22 日的研究报告中开始覆盖 Evommune，给予 “跑赢大盘” 的评级，并设定 42.00 美元的目标价。William Blair 在 12 月 1 日的研究报告中开始覆盖 Evommune，给予该股票 “跑赢大盘” 的评级。Cantor Fitzgerald 在 12 月 1 日的报告中开始覆盖 Evommune 的股票，给予该公司的 “增持” 评级。最后，Evercore ISI 在 12 月 1 日的报告中开始覆盖 Evommune 的股票，给予 “跑赢大盘” 的评级，并设定 40.00 美元的目标价。两位投资分析师对该股票给予了强烈买入评级，七位给予买入评级，一位给予持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，共识目标价为 39.17 美元。</p>
</div><p><strong>View Our Latest Research Report on Evommune</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Evommune 的最新研究报告</strong></p>
</div><h2>Evommune Trading Down 2.7%</h2>
<div class="lb-trans"><h2>Evommune 股价下跌 2.7%</h2>
</div><p>The stock has a market capitalization of $600.53 million and a PE ratio of -2.36. The business has a fifty day moving average of $18.54.</p>
<div class="lb-trans"><p>该股票的市值为 6.0053 亿美元，市盈率为-2.36。该公司的 50 日移动平均线为 18.54 美元。</p>
</div><p>Evommune (NYSE:EVMN - Get Free Report) last released its earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($6.58) by ($1.49). The company had revenue of $10.00 million during the quarter, compared to analysts' expectations of $10.00 million.</p>
<div class="lb-trans"><p>Evommune（纽约证券交易所代码：EVMN - 获取免费报告）最近在 12 月 11 日发布了其财报。该公司报告每股收益（EPS）为-8.07 美元，低于分析师的共识预期（-6.58 美元）1.49 美元。该公司在该季度的收入为 1000 万美元，而分析师的预期也是 1000 万美元。</p>
</div><h2>Institutional Trading of Evommune</h2>
<div class="lb-trans"><h2>Evommune 的机构交易</h2>
</div><p>A hedge fund recently bought a new stake in Evommune stock. Capricorn Fund Managers Ltd purchased a new stake in shares of Evommune, Inc. (NYSE:EVMN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 60,000 shares of the company's stock, valued at approximately $1,027,000. Capricorn Fund Managers Ltd owned approximately 0.19% of Evommune at the end of the most recent quarter.</p>
<div class="lb-trans"><p>一家对冲基金最近在 Evommune 股票中购买了新股份。根据该公司在最近向证券交易委员会提交的 13F 文件，Capricorn Fund Managers Ltd 在第四季度购买了 Evommune, Inc.（纽约证券交易所代码：EVMN - 免费报告）的新股份。该公司购买了 60,000 股，价值约为 1,027,000 美元。Capricorn Fund Managers Ltd 在最近一个季度末持有 Evommune 约 0.19% 的股份。</p>
</div><h2>Evommune Company Profile</h2>
<div class="lb-trans"><h2>Evommune 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.</p>
<div class="lb-trans"><p>Evommune 是一家临床阶段的生物技术公司，开发针对慢性炎症性疾病关键驱动因素的创新疗法，初步临床开发项目集中在慢性自发性荨麻疹（“CSU”）、特应性皮炎（“AD”）和溃疡性结肠炎（“UC”）上。慢性炎症是全球一个重要的健康问题，严重影响患者的生活质量，并导致危及生命的疾病。如果不加以预防，这些疾病最终会导致致命疾病，如心血管疾病、糖尿病和癌症，这些疾病占全球每五个死亡病例中的三个，并导致美国医疗系统每年约 900 亿美元的成本。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Evommune</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Do not delete, read immediately</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Evommune</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>没有人告诉你的 100 万亿 AI 故事</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Evommune Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Evommune 吗？</h2>
</div><p>Before you consider Evommune, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Evommune 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evommune wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Evommune 并不在名单上。</p>
</div><p>While Evommune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Evommune 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Evommune (NYSE:EVMN) 股价下跌 6.9% - 以下是原因